-- Edited by Josh Haynie on Wednesday 24th of September 2014 07:09:07 AM
Isiscat2011 said
Sep 23, 2014
Here is an informative article about access to Sovaldi tx since it hit the market. It is good to keep in mind that the AASLD guidelines on who to treat are just guidelines, and I'm guessing many docs will prescribe the new DAAs to all their HCV patients, regardless of liver fibrosis stage. Insurers will be hard pressed to deny coverage if docs take a hard stance on this.
So far, 70% of "targeted" docs wrote scripts for Sovaldi, and of those scripts 60% were for patients who had little or no fibrosis. Also, 70% of the scripts were for Interferon free regimens. Given this apparent willingness to prescribe tx for low fibrosis patients, and even to prescribe off-label, it seems likely that docs will be prescribing the new FDA approved DAAs liberally.
The article also reports that 47 of 50 states have been paying for Sovaldi tx (via Medicaid) and of those only half have a requirement for high fibrosis scores. We can definitely expect to see some legal challenges to public sector denials of HCV tx.
challenged indeed they will be....
i take turmeric too
good article
-- Edited by Josh Haynie on Wednesday 24th of September 2014 07:09:07 AM
Here is an informative article about access to Sovaldi tx since it hit the market. It is good to keep in mind that the AASLD guidelines on who to treat are just guidelines, and I'm guessing many docs will prescribe the new DAAs to all their HCV patients, regardless of liver fibrosis stage. Insurers will be hard pressed to deny coverage if docs take a hard stance on this.
So far, 70% of "targeted" docs wrote scripts for Sovaldi, and of those scripts 60% were for patients who had little or no fibrosis. Also, 70% of the scripts were for Interferon free regimens. Given this apparent willingness to prescribe tx for low fibrosis patients, and even to prescribe off-label, it seems likely that docs will be prescribing the new FDA approved DAAs liberally.
The article also reports that 47 of 50 states have been paying for Sovaldi tx (via Medicaid) and of those only half have a requirement for high fibrosis scores. We can definitely expect to see some legal challenges to public sector denials of HCV tx.
http://insurancenewsnet.com/oarticle/2014/09/22/sovaldi-sales-suggest-payer-tolerance-for-drug-a-558390.html#.VCG8DfBX-uY